


Ask a doctor about a prescription for TRUVADA 200 mg/245 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Truvada 200 mg/245 mg film-coated tablets
Emtricitabine/tenofovir disoproxil
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Truvada contains two active substances,emtricitabine and tenofovir disoproxil. Both active substances are antiretroviral medicines used to treat HIV infection. Emtricitabine is a nucleoside analogue reverse transcriptase inhibitor and tenofovir is a nucleotide analogue reverse transcriptase inhibitor. They are usually called NRTIs and work by interfering with the normal working of an enzyme (reverse transcriptase) that is essential for the virus to reproduce.
People infected with HIV must continue to take Truvada and other HIV medications exactly as prescribed by their healthcare providerand should remain under the care of a healthcare provider. The long-term risks and benefits of Truvada for HIV treatment are not known.
Truvada does not cure HIV infection or AIDS. You may still develop infections or other illnesses associated with HIV.
See section 2 for a list of precautions to take to avoid HIV infection.
Do not take Truvada to treat HIV or reduce the risk of getting HIV:if you are allergic to emtricitabine, tenofovir, tenofovir disoproxil, or any of the other ingredients of this medicine (listed in section 6).
If this happens, call your doctor right away.
Before taking Truvada to reduce the risk of getting HIV:
Truvada can only help reduce the risk of getting HIV before you are infected.
These can be signs of HIV infection:
Tell your doctor about any flu-like illness, either in the month before starting Truvada or at any time while taking Truvada.
Warnings and precautions
When taking Truvada to reduce the risk of getting HIV:
Ask your doctor if you have any questions about how to prevent getting HIV or giving it to others.
When taking Truvada to treat HIV or reduce the risk of getting HIV:
Bone problems (which can lead to fractures) can also occur due to damage to the kidney tubule cells (see section 4, Possible side effects).
Children and adolescents
Truvada should not be given to children under 12 years of age.
Other medicines and Truvada
Do not take Truvadaif you are already taking other medicines that contain the ingredients of Truvada (emtricitabine and tenofovir disoproxil) or any other antiviral medicine that contains tenofovir alafenamide, lamivudine, or adefovir dipivoxil.
Taking Truvada with other medicines that can harm your kidneys: it is especially important that you tell your doctor if you are taking any of these medicines. These include:
If you are taking another antiviral medicine called a protease inhibitor to treat HIV, your doctor may ask you to have blood tests to closely monitor your kidney function.
It is also important to tell your doctorif you are taking ledipasvir/sofosbuvir, sofosbuvir/velpatasvir, or sofosbuvir/velpatasvir/voxilaprevir to treat hepatitis C infection.
Taking Truvada with other medicines that contain didanosine (for HIV treatment):Taking Truvada with other antiviral medicines that contain didanosine can increase the levels of didanosine in your blood and may reduce the CD4 cell count. When medicines containing tenofovir disoproxil and didanosine are taken together, rare cases of pancreatitis and lactic acidosis (excess lactic acid in the blood) have been reported, sometimes causing death. Your doctor will carefully consider whether to treat you with combinations of tenofovir and didanosine.
Tell your doctor if you are taking any of these medicines. Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Taking Truvada with food and drink
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
If you have taken Truvada during your pregnancy, your doctor may ask you to have regular blood tests and other diagnostic tests to monitor the development of your baby. In children whose mothers took NRTIs during pregnancy, the benefit of protection against HIV outweighed the risk of side effects.
Driving and using machines
Truvada can cause dizziness. If you feel dizzy while taking Truvada, do not drive or operate tools or machines.
Truvada contains lactose
If your doctor has told you that you have an intolerance to some sugars, contact them before taking this medicine.
The recommended dose of Truvada for treating HIV is:
The recommended dose of Truvada for reducing the risk of getting HIV is:
If you have difficulty swallowing, you can use the tip of a spoon to crush the tablet. Then mix the powder with approximately 100 ml of water (half a glass), orange juice, or grape juice, and drink it immediately.
Ask your doctor if you have any questions about how to prevent getting HIV or giving it to others.
If you take more Truvada than you should
If you accidentally take more than the recommended dose of Truvada, contact your doctor or go to the nearest emergency room. Take the pack of tablets with you so you can easily describe what you have taken.
If you forget to take Truvada
It is important that you do not miss a dose of Truvada.
If you vomit within 1 hour after taking Truvada, take another tablet. You do not need to take another tablet if you vomit more than 1 hour after taking Truvada.
Do not stop taking Truvada
Do not stop taking Truvada without talking to your doctor.
Talk to your doctor right awayabout any new or unusual symptoms after stopping treatment, especially symptoms that you think may be related to hepatitis B infection.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Possible Serious Adverse Effects:
If you think you may have lactic acidosis, seek medical attention immediately.
If you notice these or any symptoms of inflammation or infection, seek medical attention immediately.
Possible Adverse Effects:
Very Common Adverse Effects
(may affect more than 1 in 10 people)
Lab tests may also show:
Common Adverse Effects
(may affect up to 1 in 10 people)
Lab tests may also show:
Uncommon Adverse Effects
(may affect up to 1 in 100 people)
Lab tests may also show:
Rare Adverse Effects
(may affect up to 1 in 1,000 people)
Damage to the renal tubule cells can be associated with muscle breakdown, bone weakening (with bone pain and sometimes resulting in fractures), muscle pain, muscle weakness, and decreased blood potassium or phosphate levels.
If you notice any of the above adverse effects or if any of the adverse effects worsen, talk to your doctor or pharmacist.
The frequency of the following adverse effects is unknown.
During HIV treatment, there may be an increase in weight and glucose and lipid levels in the blood. This may be partly related to the recovery of health and lifestyle, and in the case of blood lipids, sometimes to HIV medications themselves. Your doctor will monitor these changes.
Other Adverse Effects in Children
If you notice any of these symptoms, inform your doctor.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the bottle and carton after {CAD}. The expiration date is the last day of the month indicated.
Store in the original packaging to protect from moisture. Keep the bottle tightly closed.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Composition of Truvada
Appearance and Package Contents
Truvada film-coated tablets are blue, capsule-shaped tablets, marked on one side with the word "GILEAD" and on the other with the number "701". Truvada comes in bottles of 30 tablets. Each bottle contains a silica gel desiccant that should be kept inside the bottle to protect the tablets. The silica gel desiccant is contained in a separate pouch or container and should not be swallowed.
This medicine is available in packs of 1 bottle of 30 film-coated tablets and in packs of 90 (3 bottles of 30) film-coated tablets. Only some pack sizes may be marketed.
Marketing Authorization Holder:
Gilead Sciences Ireland UC
Carrigtohill
County Cork, T45 DP77
Ireland
Manufacturer:
Gilead Sciences Ireland UC
IDA Business & Technology Park
Carrigtohill
County Cork
Ireland
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien Gilead Sciences Belgium SPRL-BVBA Tel: + 32 (0) 24 01 35 50 | Lietuva Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 |
??????? Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 | Luxembourg/Luxemburg Gilead Sciences Belgium SPRL-BVBA Tel: + 32 (0) 24 01 35 50 |
Ceská republika Gilead Sciences s.r.o. Tel: + 420 (0) 910 871 986 | Magyarország Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Danmark Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1849 | Malta Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Deutschland Gilead Sciences GmbH Tel: + 49 (0) 89 899890-0 | Nederland Gilead Sciences Netherlands B.V. Tel: + 31 (0) 20 718 36 98 |
Eesti Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 | Norge Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1849 |
Ελλ?δα Gilead Sciences Ελλ?ς Μ.ΕΠΕ. Τηλ: + 30 (0) 210 8930 100 | Österreich Gilead Sciences GesmbH Tel: + 43 (0) 1 260 830 |
España Gilead Sciences, S.L. Tel: + 34 (0) 91 378 98 30 | Polska Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 |
France Gilead Sciences Tél: + 33 (0) 1 46 09 41 00 | Portugal Gilead Sciences, Lda. Tel: + 351 (0) 21 7928790 |
Hrvatska Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 | România Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Ireland Gilead Sciences Ireland UC Tel: + 353 (0) 214 825 999 | Slovenija Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Ísland Gilead Sciences Sweden AB Sími: + 46 (0) 8 5057 1849 | Slovenská republika Gilead Sciences Slovakia s.r.o. Tel: + 421 (0) 232 121 210 |
Italia Gilead Sciences S.r.l. Tel: + 39 (0) 02 439201 | Suomi/Finland Gilead Sciences Sweden AB Puh/Tel: + 46 (0) 8 5057 1849 |
Κ?pρος Gilead Sciences Ελλ?ς Μ.ΕΠΕ. Τηλ: + 30 (0) 210 8930 100 | Sverige Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 |
Latvija Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 | United Kingdom Gilead Sciences Ltd. Tel: + 44 (0) 8000 113 700 |
Date of Last Revision of this Leaflet:
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for TRUVADA 200 mg/245 mg FILM-COATED TABLETS – subject to medical assessment and local rules.